Jodi Devlin insider trades: TriSalus Life Sciences (TLSI) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jodi reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 16, 2026 | TLSI | ↓ Sell | 3,207 | $4.11 | $13K | Direct | Mar 20, 2026 (4d) |
| May 19, 2025 | TLSI | ↓ Sell | 4,764 | $5.18 | $25K | Direct | May 21, 2025 (2d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other TLSI insiders
Open-market trades in the last 12 months
About Jodi Devlin's insider trades
Jodi Devlin is Chief of Clinical Operations at TriSalus Life Sciences (TLSI). Since May 19, 2025, Jodi has reported no open-market purchases and 2 sales worth $38K on SEC Form 4. In the last 12 months: 1 sale ($13K).
Their filings also include grants and awards (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every TLSI insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.